PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23912706-0	2013	Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells.	Pemetrexed	0-10	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	25-30	
21262916-0	2011	Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.	Pemetrexed	139-149	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	25-68	
21262916-3	2011	This retrospective study aimed to assess the role of excision repair cross-complementing group-1 (ERCC1) and thymidylate synthase (TS) in tumors, and correlate expression levels and polymorphisms of these key determinants of drug activity with the outcome of MPM patients treated with carboplatin/pemetrexed in first-line setting.	Pemetrexed	297-307	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	98-103	
31479512-7	2020	Based on concurrent biomarker expression, combinations of immunotherapy with platinum (ERCC1 negativity) or with doxorubicin, epirubicin, or etoposide (TOP2A positivity), have a higher probability of response while combinations with irinotecan or topotecan (TOPO1 positivity), with gemcitabine (RRM1 negativity), and fluorouracil, pemetrexed, or capecitabine (TS negativity) may be of less benefit.	Pemetrexed	331-341	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	87-92	
29572009-9	2018	CONCLUSION: A combination of ERCC1 and ERCC2 polymorphisms may predict OS among pemetrexed/platinum treated advanced non-squamous NSCLC patients.	Pemetrexed	80-90	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	29-34	
27893326-13	2017	Median OS was 8.0 (paclitaxel and pemetrexed) versus 9.6 (cisplatin and pemetrexed) months for ERCC1-positive patients (HR, 1.11; 95% CI, 0.85 to 1.44), and 10.3 (paclitaxel and pemetrexed) versus 11.6 (cisplatin and pemetrexed) months for ERCC1-negative patients (HR, 0.99; 95% CI, 0.73 to 1.33; interaction P = .64).	Pemetrexed	72-82	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	95-100	
27893326-13	2017	Median OS was 8.0 (paclitaxel and pemetrexed) versus 9.6 (cisplatin and pemetrexed) months for ERCC1-positive patients (HR, 1.11; 95% CI, 0.85 to 1.44), and 10.3 (paclitaxel and pemetrexed) versus 11.6 (cisplatin and pemetrexed) months for ERCC1-negative patients (HR, 0.99; 95% CI, 0.73 to 1.33; interaction P = .64).	Pemetrexed	72-82	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	95-100	
27893326-13	2017	Median OS was 8.0 (paclitaxel and pemetrexed) versus 9.6 (cisplatin and pemetrexed) months for ERCC1-positive patients (HR, 1.11; 95% CI, 0.85 to 1.44), and 10.3 (paclitaxel and pemetrexed) versus 11.6 (cisplatin and pemetrexed) months for ERCC1-negative patients (HR, 0.99; 95% CI, 0.73 to 1.33; interaction P = .64).	Pemetrexed	72-82	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	95-100	
27502726-5	2016	RESULTS: The best-validated predictive biomarkers for efficacy are currently ERCC1, RRM1, and TS for platinum agents, gemcitabine and pemetrexed, respectively.	Pemetrexed	134-144	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	77-82	
25028118-0	2014	Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients.	Pemetrexed	92-102	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	31-36	
25028118-1	2014	PURPOSE: We presented retrospective analysis of up to five polymorphisms in TS, MTHFR and ERCC1 genes as molecular predictive markers for homogeneous Caucasian, non-squamous NSCLC patients treated with pemetrexed and platinum front-line chemotherapy.	Pemetrexed	202-212	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	90-95	
25246386-0	2014	Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.	Pemetrexed	109-119	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	35-40	
25246386-4	2014	The aim of this retrospective multicenter study was to assess the correlation between TS, 5,10-methylenetetrahydrofolate reductase (MTHFR) and excision repair cross-complementing group 1 (ERCC1) gene polymorphisms and the efficacy of pemetrexed-based first-line chemotherapy of mesothelioma patients.	Pemetrexed	234-244	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	143-186	
25246386-4	2014	The aim of this retrospective multicenter study was to assess the correlation between TS, 5,10-methylenetetrahydrofolate reductase (MTHFR) and excision repair cross-complementing group 1 (ERCC1) gene polymorphisms and the efficacy of pemetrexed-based first-line chemotherapy of mesothelioma patients.	Pemetrexed	234-244	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	188-193	
23912706-8	2013	Combining resveratrol with pemetrexed resulted in a synergistic cytotoxic effect, accompanied with the reduction of phospho-p38 MAPK and ERCC1 protein levels, and a DNA repair capacity.	Pemetrexed	27-37	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	137-142	
23912706-10	2013	In this study, for the first time, we have demonstrated the synergistic effect of combined treatment with resveratrol and pemetrexed in human NSCLC cells through downregulation of the MKK3/6-p38 MAPK-ERCC1 signal, suggesting a potential benefit of combining resveratrol and pemetrexed to treat lung cancer in the future.	Pemetrexed	122-132	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	200-205	
23523421-0	2013	Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin.	Pemetrexed	108-118	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	25-30	
23523421-11	2013	Protein expressions of TS and ERCC1 were associated with clinical outcomes in patients with pulmonary adenocarcinoma who were treated with pemetrexed/cisplatin as first-line chemotherapy.	Pemetrexed	139-149	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	30-35	
23482788-8	2013	For patients with high expression of ERCC1 and tubulin, uracil-tegafur, pemetrexed, and gemcitabine may be the alternative agents for personalized chemotherapy.	Pemetrexed	72-82	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	37-42	
23790173-7	2013	Patients with low mRNA expression of ERCC1 or TYMS preferred higher DCR to cisplatin and pemetrexed than those with high expression (P = 0.39 and P= 0.11).	Pemetrexed	89-99	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	37-42